Clinical Trial Update: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial PAveMenT is evaluating the combination of palbociclib and avelumab in metastatic AR-positive triple-negative breast cancer and is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• BAVENCIO (AVELUMAB)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer | Phase 1 | Status: RECRUITING